

Effect of Sodium Butyrate on *LHX1* mRNA Expression as a Transcription Factor of HDAC8 in Human Colorectal Cancer Cell Lines

Mahsa Ghiaghi ¹, Flora Forouzesh ^{1*}, and Hamzeh Rahimi ²

1. Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

2. Department of Molecular Medicine, Pasteur Institute of Iran, Tehran, Iran

Abstract

Background: LHX1 is an important transcription factor for the *HDAC8* gene. The aim of this study was to investigate the effect of Sodium Butyrate (SB), as a histone deacetylase inhibitor, on the expression of *LHX1* gene in colorectal cancer cell lines.

Methods: HT-29 and HCT-116 cell lines were treated with 6.25 to 200 mM concentrations of SB at 24, 48, and 72 hr. The cytotoxicity effect on cell viability was evaluated by MTT assay. The 50% Inhibiting Concentration (IC₅₀) was determined graphically. Quantitative real-time PCR was performed to investigate the *LHX1* mRNA expression level.

Results: Our study revealed that SB inhibited the proliferation of these cell lines in a concentration and time-dependent manner. The IC₅₀ values for HT-29 cell line were 65, 18.6, and 9.2 mM after 24, 48, and 72 hr of treatment, respectively. The IC₅₀ values for HCT-116 cell line were 35.5, 9.6, and 10 mM after 24, 48, and 72 hr of treatment, respectively. Furthermore, real-time PCR findings demonstrated that the *LHX1* mRNA expression in treated HT-29 cell line significantly increased in comparison with untreated cells (p<0.05). However, in treated HCT-116 cell line, SB led to a significant decrease in the level of *LHX1* mRNA (p<0.05), as compared to untreated cells.

Conclusion: In this study, different effects of SB on *LHX1* mRNA expression level were revealed in two distinct human colorectal cancer cell lines.

Avicenna J Med Biotech 2019; 11(4): 317-324

Keywords: Colorectal cancer, HCT-116 cells, Histone deacetylase inhibitors, Humans, Transcription factors

Introduction

Colorectal cancer is one of the most common cancers in the world including 9% of all cancers ¹. This cancer is the second common cancer and the fourth cause of death due to cancer globally ². Dysregulation in the epigenetic mechanisms, including histone acetylation, is one of the main factors contributing to the colorectal cancer ³⁻⁵. Acetylation, a process in which the chromatin structure and gene expression ⁶ are modified, is controlled by two types of enzymes, Histone Acetylases (HAT) and Histone Deacetylases (HDACs) ⁷. The change in acetylation status in cancer cells such as prostate ⁸, colon ⁹, and gastric ¹⁰ cancers has been linked to the increased expression of certain HDAC in indefinite patterns.

HDACs directly interact with transcription factors and can regulate the expression of a large number of genes ¹¹. LHX1 (LIM Homeobox1) protein is one of the transcription factors involved in the transcription of *HDAC8* gene ¹². Moreover, it has different functions

including regulation of cell fate, cellular skeleton organization, and tumor formation ¹³⁻¹⁶. The *LHX1* expression has been reported in human cancers such as ovarian cancer, kidney carcinoma, leukemia cells, and epithelial cells ¹⁷.

Histone Deacetylase Inhibitors (HDACi) can change the balance between HAT and HDAC, and also lead to the acetylation of histone and non-histone proteins that induce transcription and related molecular effects ¹⁸. Some processes involved in the inhibition of HDAC are apoptosis, necrosis, growth inhibition, and differentiation ¹⁹⁻²¹. One of the HDACi is Sodium Butyrate (SB) ^{22,23}. The produced butyrate in the colon may inhibit the development of colon cancer and protect against colon cancer ^{24,25}. One of the functions of butyrate is its anti-inflammatory effect that plays a crucial role in inhibiting the histone deacetylase ²⁶. In addition, SB influences the gene expression through binding to the transcription factors. Epigenetic regulation orches-

trates various physiological procedures, comprising transcription, replication, and repair from developmental to differentiated stages and emerges with a pivotal role in the process of tumorigenesis²⁷⁻²⁹. The understanding of these mechanisms might contribute to the optimization of prognostic and diagnostic systems, as well as the generation of novel and targeted therapeutic approaches. In the present study, the effect of SB on *LHX1* mRNA expression, as a transcription factor of the *HDAC8* gene, in HT-29 and HCT116 human colorectal cell lines was investigated. It is expected that the expression of *LHX1* in treated cells would be decreased, in comparison with untreated cells. Our results showed that in HCT-116 cells, the expression of *LHX1* was decreased; however, in HT-29 cells this expression level was increased, compared with untreated cells. One of the explanations for this may be the different tissue origin of these two cell lines given the fact that HT-29 is adenocarcinoma and HCT-116 is carcinoma. Furthermore, these cell lines represent a wide range of cancer characteristics; HCT-116 has a wild-type p53 response while being deficient in mismatch repair, whereas the HT-29 is p53 deficient and an unstable cell line³⁰. Molecular mechanisms may affect the underlying function in each cell line.

Materials and Methods

Cell culture

HT-29 and HCT116 human colorectal cell lines were purchased from Pasteur Institute of Iran (Tehran, Iran). HT-29 and HCT116 cells were cultured in RPMI 1640 and DMEM (Dulbecco's Modified Eagle's Medium) (Gibco, Germany), respectively, which was supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Germany) and 1% penicillin-streptomycin (100 IU/ml and 100 µg/ml, respectively) (Dacell, Iran). Cells were incubated at 37°C under a humidified atmosphere of 95% air and 5% CO₂ (v/v). Monolayer cells were harvested by 0.25% trypsin-EDTA (Gibco, Germany).

SB treatment

Optimization of cell numbers in 96-well plates (Spl life sciences, Korea) was performed for 24, 48, and 72 hr of incubation time. A total of 50×10³ cells per well (The optimized cell number) were seeded in 96-well plates and incubated for 24 hr. SB was dissolved in sterile water with a 1 molar concentration of stock solution for *in vitro* studies, which was further diluted to the working concentration (6.25 to 200 mM) in culture media. All cell lines were then treated with SB at the concentrations ranging from 6.25 to 200 mM for 24, 48, and 72 hr. Untreated cells (0 mM) and cells treated with dimethyl sulfoxide (DMSO) 20% were considered as negative and positive controls, respectively.

Cytotoxicity assay

The cytotoxic effect of SB (Biobasic, Canada Inc.) in HT-29 and HCT-116 colorectal cell lines was de-

termined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, USA) and was compared with the untreated cells (0 mM) as a control group. Briefly, 100 µl of the MTT stock solution (5 mg/ml in PBS) was added to each well to attain a final concentration of 0.5 mg/ml in RPMI-1640 without phenol red culture (Biosera, France). After 4 hr of incubation, the supernatants were aspirated; the formazan crystals in each well were dissolved in 50 µl DMSO and the absorbance was measured at 546 nm using an ELISA reader (Garni Medical Eng. Co., Tehran, Iran). Each SB concentration was assayed in separated wells and each experiment was repeated at least 3 times. Cell viabilities were calculated using the following formula:

Cell viability rate (%) = (OD₅₄₆ of treated cells / OD₅₄₆ of control cells) × 100 %.

Afterwards, the half-maximal growth inhibitory concentration (IC₅₀) values were estimated from dose response curves by applying linear regression analysis via the JavaScript version of PolySolve (07.20.2013) software.

RNA extraction and cDNA synthesis

A total of 3×10⁶ HT-29 and HCT-116 human colorectal cells were seeded in 6-well plates (Spl life sciences, Korea) in 2 ml of RPMI-1640 and DMEM medium supplemented with 2% FBS, respectively, and were treated with different concentrations of SB (6.25 to 200 mM) for 24 and 48 hr. After the end of incubation time, total cellular RNA was extracted from the cancer cells treated with SB and untreated cells using RNX- Plus Solution (Sinaclon, Iran). The quality and quantity of extracted RNA were measured with agarose gel electrophoresis and a spectrophotometer (Eppendorf, Germany). Complementary DNA (cDNA) was synthesized with 2000 ng total RNA using a cDNA synthesis kit (Yektatajhez, Iran) according to the manufacturer's protocol.

Quantitative real-time PCR (qRT-PCR)

The qRT-PCR analysis was carried out for *LHX1* gene using RQ-PCR SYBR Green I system Light Cycler 96 (Roche Diagnostics, Germany). The *GAPDH* (Housekeeping gene) was used as an internal control. Reactions were prepared in duplicate using 2X SYBR Green Supermix (Pishgam, Iran) according to manufacturer's instructions to a final volume of 20 µl. The following conditions were used: 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing, and extension at 60°C for 60s. Quality of PCR products was evaluated by generating a melting curve, which was also used to verify the absence of PCR artifacts (Primer-dimers) or nonspecific PCR products. Variations in relative gene expressions between treated cells and control group (Untreated cells) cDNA samples were identified with Relative Expression Software Tool 9 (REST 9, Qiagen) using the 2^{-ΔΔCT} method. The primers (10 pmol) are listed in table 1.

Table 1. Primer sequences used in quantitative polymerase chain reaction (qRT-PCR)

Name	Forward primer sequence (5'-3')	Reverse primer sequence (5'-3')	Accession number
<i>GAPDH</i>	GAAGGTGAAGGTCGGAGTC	GAAGATGGTGATGGGATTTC	NM_001289745.2
<i>LHX1</i>	TCTCCAGGGAAGGCAAACCT	CGAAACACCGGAAGAAGTC	NM_005568.4

Data analysis

Ct values were adjusted, taking into account primer efficiencies for each gene when calculating $2^{-\Delta\Delta CT}$ values. Expression data for each target gene was also normalized to the housekeeping gene (*GAPDH*) and fold change calculations were made based on Schmittgen and Livak's method by using REST 9 and LinRegPCR softwares. The level of statistical significance was set at $p < 0.05$.

Results

The effect of SB on the cell viability of HT-29 and HCT-116 human colorectal cancer cell lines

To investigate the role of HDAC on the proliferation of colorectal cancer cells, HT-29, and HCT-116 human colorectal cell lines were treated with various concentrations of SB (From 6.25 to 200 mM) for 24, 48, and 72 hr. Then, the cytotoxicity effect of SB on cancer cells was investigated with MTT assay. The viability of HT-29 and HCT-116 cells was further decreased by higher doses of SB (6.25 to 200 mM). Our study revealed that SB could inhibit the proliferation of HT-29 (Figure 1A) and HCT-116 (Figure 1B) cell lines in a concentration and time-dependent manner.

The IC_{50} calculated for SB

The effective concentration of SB for the determination of the half-maximal inhibitory concentration (IC_{50}) value was obtained by regression analyses of concentration-inhibition curves. The IC_{50} value for HT-29 human colorectal cell line was achieved as 65 mM for the 24 hr of SB treatment, 18.6 mM for 48 hr of SB treatment, and 9.2 mM for 72 hr of SB treatment (Figure 2). As well, the IC_{50} value for HCT-116 human colorectal cell line was 35.5 mM for 24 hr of SB treatment, 9.6 mM for 48 hr of SB treatment, and 10 mM for 72 hr of SB treatment (Figure 3). The IC_{50} of SB in HT-29 and HCT-116 human colorectal cancer cell lines was significantly decreased in 24, 48, and 72 hr in a time-dependent manner.

Quantitative real-time PCR

HT-29 cell line: The effect of SB was examined on *LHX1* mRNA expression in HT-29 human colorectal cancer cell line *in vitro* by incubating the cells in 6.25, 12.5, 25, 50, and 100 mM concentrations of SB for 24 and 48 hr. The concentrations of 150 and 200 mM were found to be toxic. After 24 hr of incubation with 6.25 to 100 mM concentrations of SB, *LHX1* mRNA expression significantly increased in all concentrations, compared with untreated cells as a control group ($p < 0.05$) (Figure 3A); however, in higher concentration of SB, this fold change decreased in comparison with 6.25




Figure 1. Cell viability in cancer cells treated with sodium butyrate (SB). A) HT-29 colorectal cell line was treated with 6.25 to 200 mM concentrations of SB at 37°C for 24, 48, and 72 hr of incubation. B) HCT-116 colorectal cell line was treated with 6.25 to 200 mM concentrations of SB at 37°C for 24, 48, and 72 hr of incubation. Cell viabilities were evaluated using MTT assay and calculated as a ratio of the control. Control (+): cells treated with dimethyl sulfoxide (DMSO) 20% and untreated cells (0 mM) as negative control. All experiments were performed in triplicate.

mM concentration. This is probably owing to the very low numbers of cells at higher concentrations of SB treatment causing a denominator effect. The increased SB concentrations in the treatment were found to result in reduced cell numbers and enhanced cell death. After 48 hr of incubation, *LHX1* mRNA expression was significantly enhanced at concentrations of 6.25, 25, 50, and 100 mM SB, compared with untreated cells as a control group ($p < 0.05$). Nonetheless, there was no significant increase in the concentration of 12.5 mM ($p > 0.05$) (Figure 4).

HCT-116 cell line

Also, the effects of SB on *LHX1* mRNA expression in HCT-116 human colorectal cancer cell line were investigated *in vitro* by incubating the cells in 6.25, 12.5, 25, 50, and 100 mM concentrations of SB for 24 and 48 hr. 24 hr after treatment with SB, *LHX1* mRNA expression significantly decreased at concentrations of 6.25, 12.5, 50, and 100 mM SB, compared with untreated cells as a control group ($p < 0.05$). However, there was no significant decrease at the concentration of 25 mM ($p > 0.05$) (Figure 5A). Likewise, 48 hr after

The Effect of Sodium Butyrate on the *LHX1* mRNA Expression in Colorectal Cancer Cell Line




Figure 2. Regression analyses to calculate the 50% inhibiting concentration (IC_{50}) values for effect of sodium butyrate (SB) on HT-29 human colorectal cell line. The horizontal axis (x) represents the concentration (mM) and the vertical axis (y) represents the percentage of the cell viability. A) The IC_{50} value was 65 mM for 24 hr after treatment, B) 18.6 mM for 48 hr after treatment, and C) 9.2 mM for 72 hr after treatment.

treatment with SB, *LHX1* mRNA expression was significantly down-regulated in all concentrations of 6.25 to 100 mM SB, compared with untreated cells as a control group ($p < 0.05$) (Figure 5B).

Discussion

Acetylation is a chief part of the gene expression regulation^{31,32} and is controlled by the opposite function of the HAT and HDAC enzymes⁷. The dysregulated expression of HDAC enzymes is often seen in cancers^{31,32}. HDAC can regulate the expression of a large number of genes by direct interaction with transcription factors such as P53, E2f, Stat3, NF- κ B, retinoblastoma protein, and TFIIE¹¹ affecting angiogene-




Figure 3. Regression analyses to calculate the 50% inhibiting concentration (IC_{50}) values for effect of sodium butyrate (SB) in HCT-116 human colorectal cell line. The horizontal axis (x) represents the concentration (mM) and the vertical axis (y) represents the percentage of the cell viability. A) The IC_{50} value was 35.5 mM for 24 hr after treatment, B) 9.6 mM for 48 hr after treatment, and C) 10 mM for 72 hr after treatment.

sis, cell cycle arrest, apoptosis, and the differentiation of different cell types^{33,34}. *LHX1* is one of the transcription factors involved in the transcription of *HDAC8* gene¹². Despite the normal expression of *HDAC8* in healthy organs, its expression in tumor tissues is up-regulated^{35,36}. The selective pharmacological inhibition of HDACi represents a novel treatment for cancer therapy^{18,33,34,37,38}. One of the HDACi is SB^{22,23}. In 2010, Ooi *et al* examined the effects of SB and their analogs in HT-29 cancer cells and observed that the 5 mmol/L concentration of SB resulted in decreased proliferation, increased apoptosis, and the reduction of HDAC activity³⁹. The findings of the presents study are consistent with the above information. The cytotoxicity of SB in HT-29 and HCT-116 human colorectal




Figure 4. The effect of sodium butyrate (SB) on the *LHX1* mRNA expression in HT-29 cell line. A) Cells were cultured for 24 hr with 6.25 to 100 mM concentrations of SB at 37°C. B) Cells were cultured for 48 hr with 6.25 to 100 mM concentrations of SB at 37°C. *LHX1* mRNA expression was investigated using qRT-PCR. *GAPDH* was used as the internal control. *LHX1* mRNA expression increased in treated cells compared to control (0 mM). * Indicates a significant increase ($p < 0.05$) vs. controls. All experiments were performed in duplicate.

cancer cell lines was examined by using MTT assay. Our results revealed that SB could inhibit the proliferation of both HT-29 and HCT-116 cell lines in a concentration- and time-dependent manner. In HT-29 cell line, the viability of cells decreased to 52, 52, and 50% after 24, 48, and 72 hr of treatment, respectively. Besides, in HCT-116 cell line, the cell viability was diminished to 68, 51 and 54% after 24, 48, and 72 hr of treatment, respectively.

In the present study, for the first time, the effect of SB on the *LHX1* mRNA expression was investigated. In 2009, Haberland *et al* examined the relationship between *HDAC8* and homeobox transcription factors of *LHX1* and *Otx2* using PCR techniques in mice and concluded that the inappropriate expression of these transcription factors suppressed *HDAC8*⁴⁰. In 2011, Dormoy *et al* reviewed the transcription factor of *LHX1* as a new oncogene in kidney cancer cells. They showed *LHX1* gene was re-expressed in kidney cancer and it is expressed in large quantities in kidney cancer cells, whereas in the normal kidney cells, it appears with a low expression level. On the other hand, they identified that the reduction of *LHX1* expression can lead to an increase in apoptosis and a decrease in cell proliferation after 72 hr⁴¹. In addition, Saha *et al* have




Figure 5. The Effect of sodium butyrate (SB) on *LHX1* mRNA expression in HCT-116 cell line. A) Cells were cultured for 24 hr with 6.25 mM to 100 mM of SB at 37°C. B) Cells were cultured for 48 hr with 6.25 mM to 100 mM of SB at 37°C. *LHX1* mRNA expression investigated using qRT-PCR. *GAPDH* was used as an internal control. *LHX1* mRNA expression decreased in treated cells compared to control (0 mM). * Indicates a significant reduction ($p < 0.05$) vs. controls. All experiments were performed in duplicate.

assessed the effects of an *HDAC8* inhibitor on the transcription factors of *Otx2* and *LHX1* in mice. Their results depicted that *HDAC8* suppresses the inappropriate expression of *Otx2* and *LHX1* and these two transcription factors are adjusted by *HDAC8*⁴². Also, according to the literature, it was found that butyrate is able to stop cell cycle, differentiation, and apoptosis in a number of cell lines by inhibiting *HDAC*⁴³⁻⁴⁵. SB affects the expression of genes by binding to the transcription factors. In this study, the effect of SB on *LHX1* as a transcription factor of *HDAC8* in colorectal cancer cell lines was investigated. Existing documents have shown the inappropriate expression of *LHX1* in cancers that leads to the increased transcription, growth, and proliferation, as well as inhibition of cancer cell apoptosis^{17,41}. In the current study, it was expected that SB would act as a drug reducing the expression of *LHX1*. Our findings showed that treatments with SB significantly decreased the expression of *LHX1* in HCT-116 cells in comparison with untreated cells ($p < 0.05$). However, to our surprise, the expression of *LHX1* significantly increased in HT-29 cell line, compared with untreated cells. Our results are well in line with that of Rocha *et al* that observed different effects of SB, as *HDACi*, on the expression of Estrogen Receptor (*ERα*). They expected that SB would lead to an increase in the *ERα* expression, while the opposite was found and the *ERα* expression was reduced⁴⁶.

They suggested that treatment duration time and used concentrations may be critical in these effects ⁴⁶. According to our results, Wang *et al* showed that HDACi could, *via* HDAC8/YY1, cause suppression of mutant P53 in breast cancer. HDAC8 reacts with YY1 transcription factor and adjusts the transcriptional activity. They figured out that treatment with SAHA and SB can inhibit the HDAC8 and YY1 association, enhance the YY1 acetylation, and eventually suppress the YY1-induced transcription of p53. They, also, determined that the network of HDAC8 and YY1 prevents the proliferation of breast cancer cells ⁴⁷.

Conclusion

The current study indicated that SB had anticancer activities and inhibits the growth of HT-29 and HCT-116 human colorectal cancer cell lines. Moreover, the results of this study showed that *LHX1* mRNA expression level was significantly different between two human colorectal cancer cell lines (HT-29 and HCT-116) due to SB treatment. In HT-29 human colorectal cell line, the significant increase of *LHX1* mRNA expression was observed after 24 and 48 *hr* of incubation time. On the contrary, SB led to a significantly down-regulated *LHX1* expression level at 24 and 48 *hr* of incubation time in HCT-116 human colorectal cell line. Altogether, these results indicated that there is no similar effect of SB on these different cell lines. Worthy of note, the histopathology origins of the used human colorectal cell lines in this study are distinguished. HT-29 is a cell line with adenocarcinoma origin derived from colon ascendens and colon with Dukes' C stage (Involvement of lymph nodes) ^{48,49}. HCT-116, on the other hand, has a carcinoma tissue origin and is derived from colon ascendens with Dukes' D stage (Wide-spread metastases) ⁵⁰⁻⁵². Moreover, the molecular features of these colon cancer cell lines are different ⁵³; thus, their response to drugs is supposed to be distinct. SB might be capable of both repressing and inducing the expression of different genes. In this study, the expression of *LHX1* gene was investigated in untreated and treated colorectal cells and different effects of SB on *LHX1* mRNA expression were revealed in two different human colorectal cancer cell lines. Future studies are needed to evaluate the effect of SB on *LHX1* mRNA expression in other human colorectal cancer cell lines as well as other cancer cell lines.

Acknowledgement

This paper has been resulted from MSc thesis of Mahsa Ghiaghi, student at Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

References

- Haggard FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rect Surg 2009;22(4):191-197.

- Rafieemaneh H, Mohammadian-Hafshejani A, Ghoncheh M, Sepehri Z, Shamlou R, Salehiniya H, et al. Incidence and mortality of colorectal cancer and relationships with the human development index across the world. Asian Pac J Cancer Prev 2016;17(5):2465-2473.
- Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21(35):5427-5440.
- Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Drug Discov 2002;1(4):287-299.
- Iizuka M, Smith MM. Functional consequences of histone modifications. Curr Opin Genet Dev 2003;13(2):154-160.
- Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 2006;23(3):289-296.
- Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011;21(3):381-395.
- Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59(2):177-189.
- Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281(19):13548-13558.
- Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92(12):1300-1304.
- Lin HY, Chen CS, Lin SP, Weng JR, Chen CS. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006;26(4):397-413.
- Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today 2015;20(6):718-735.
- Way JC, Chalfie M. mec-3, a homeobox-containing gene that specifies differentiation of the touch receptor neurons in *C. elegans*. Cell 1988;54(1):5-16.
- Sánchez-García I, Rabbitts TH. The LIM domain: a new structural motif found in zinc-finger-like proteins. Trends Genet 1994;10(9):315-320.
- Bridwell JL, Price JR, Parker GE, Schiller AM, Sloop KW, Rhodes SJ. Role of the LIM domains in DNA recognition by the Lhx3 neuroendocrine transcription factor. Gene 2001;277(1):239-250.
- Yaden BC, Savage JJ, Hunter CS, Rhodes SJ. DNA recognition properties of the LHX3b LIM homeodomain transcription factor. Mol Biol Rep 2005;32(1):1-6.
- Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB, et al. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics 2009;2:71.

18. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov* 2006;5(9):769-784.
19. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. *Lancet* 2005;366(9485):549-555.
20. Williams JA, Barreiro CJ, Nwakanma LU, Lange MS, Kratz LE, Blue ME, et al. Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery. *Ann Thorac Surg* 2006;81(6):2235-2242.
21. Almeida AM, Murakami Y, Baker A, Maeda Y, Roberts IA, Kinoshita T, et al. Targeted therapy for inherited GPI deficiency. *New Engl J Med* 2007;356(16):1641-1647.
22. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. *J Nutr* 2002;132(5):1012-1017.
23. Emenaker NJ, Calaf GM, Cox D, Basson MD, Qureshi N. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. *J Nutr* 2001;131(11 Suppl):3041S-3046S.
24. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. *Clin Cancer Res* 2001;7(4):962-970.
25. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. *J Clin Invest* 2001;108(9):1321-1330.
26. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. *J Appl Microbiol* 1991;70(6):443-459.
27. Van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. *J Clin Oncol* 2011;29(10):1382-1391.
28. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. *Cell* 2012;150(1):12-27.
29. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? *Cancer cell* 2012;22(1):9-20.
30. Danny CW, Waby JS, Chirakkal H, Staton CA, Corfe BM. Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. *Mol Cancer* 2010;9(1):276.
31. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. *J Cell Physiol* 2000;184(1):1-6.
32. Timmermann S, Lehrmann H, Poleskaya A, Harel-Bellan A. Histone acetylation and disease. *Cell Mol Life Sci* 2001;58(5):728-736.
33. Hildmann C, Riester D, Schwienhorst A. Histone deacetylases—an important class of cellular regulators with a variety of functions. *Appl Microbiol Biotechnol* 2007;75(3):487-497.
34. Riester D, Hildmann C, Schwienhorst A. Histone deacetylase inhibitors—turning epigenetic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. *Appl Microbiol Biotechnol* 2007;75(3):499-514.
35. Song S, Wang Y, Xu P, Yang R, Ma Z, Liang S, et al. The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma. *Int J Oncol* 2015;47(5):1819-1828.
36. Wang Y, Xu P, Yao J, Yang R, Shi Z, Zhu X, et al. RETRACTED ARTICLE: MicroRNA-216b is down-regulated in human gastric adenocarcinoma and inhibits proliferation and cell cycle Progression by targeting oncogene HDAC8. *Target Oncol* 2016;11(2):197-207.
37. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. *Nat Rev Cancer* 2006;6(1):38-51.
38. J Shuttleworth SJ, G Bailey SG, Townsend PA. Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. *Curr Drug Targets* 2010;11(11):1430-1438.
39. Ooi CC, Good NM, Williams DB, Lewanowitsch T, Cosgrove LJ, Lockett TJ, et al. Efficacy of butyrate analogues in HT-29 cancer cells. *Clin Exp Pharmacol Physiol* 2010;37(4):482-489.
40. Haberland M, Mokalled MH, Montgomery RL, Olson EN. Epigenetic control of skull morphogenesis by histone deacetylase 8. *Genes Dev* 2009;23(14):1625-1630.
41. Dormoy V, Beraud C, Lindner V, Thomas L, Coquard C, Barthelmebs M, et al. LIM-class homeobox gene Lim1, a novel oncogene in human renal cell carcinoma. *Oncogene* 2011;30(15):1753-1763.
42. Saha A, Pandian GN, Sato S, Taniguchi J, Hashiya K, Bando T, et al. Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity. *Bioorg Med Chem* 2013;21(14):4201-4209.
43. Davie JR. Inhibition of histone deacetylase activity by butyrate. *J Nurt* 2003;133(7 Suppl):2485S-2493S.
44. Danny CW, Waby JS, Chirakkal H, Staton CA, Corfe BM. Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. *Mol Cancer* 2010;9(1):276.
45. Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD, et al. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. *Mol Cancer* 2010;9(1):275.
46. Rocha W, Sanchez R, Deschênes J, Auger A, Hebert E, White JH, et al. Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells. *Mol Pharmacol* 2005;68(6):1852-
47. Wang ZT, Chen ZJ, Jiang GM, Wu YM, Liu T, Yi YM, et al. Histone deacetylase inhibitors suppress mutant p53

transcription via HDAC8/YY1 signals in triple negative breast cancer cells. *Cell Signal* 2016;28(5):506-515.

48. Fogh J, (eds). *Human Tumor Cell in Vitro*. New York, USA: Plenum Press; 1975. 550 p.
49. Cajot JF, Sordat I, Silvestre T, Sordat B. Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. *Cancer Res* 1997;57(13): 2593-2597.
50. Brattain MG, Brattain DE, Fine WD, Khaled FM, Marks ME, Kimball PM, et al. Initiation and characterization of cultures of human colonic carcinoma with different biological characteristics utilizing feeder layers of confluent fibroblasts. *Oncodev Biol Med* 1981;2(5):355-366.
51. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. *Cancer Res* 1981;41(5):1751-1756.
52. Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JK, et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. *Oncogene* 1995; 10(1):33-37.
53. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, et al. Epigenetic and genetic features of 24 colon cancer cell lines. *Oncogenesis* 2013;2(9):e71.